Development and validation of prediction models for health-related quality of life outcomes after breast cancer surgery and reconstruction

Journal Article (2026)
Author(s)

Elfi M. Verheul (Dutch Institute for Clinical Auditing, Erasmus MC)

Maria Margarete Karsten (Charité Universittsmedizin Berlin)

Pimrapat Gebert (Charité Universittsmedizin Berlin)

Lea Doppelbauer (Charité Universittsmedizin Berlin)

Simona Borstnar (Institute of Oncology Ljubljana)

Sabine Siesling (University of Twente, Netherlands Comprehensive Cancer Organization (IKNL))

Anne M. Stiggelbout (Leiden University Medical Center, TU Delft - Biomechanical Engineering)

Judith Rietjens (Erasmus MC, TU Delft - DesIgning Value in Ecosystems)

Dirk Snelders (TU Delft - Creative Processes)

More Authors (External organisation)

DOI related publication
https://doi.org/10.1016/j.ejso.2026.111466 Final published version
More Info
expand_more
Publication Year
2026
Language
English
Journal title
European Journal of Surgical Oncology
Issue number
4
Volume number
52
Article number
111466
Downloads counter
6
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

BackgroundPredictions of Health-Related Quality of Life (HRQoL) outcomes could support realistic recovery expectations after breast cancer (BC) surgery. We aimed to develop and validate prediction models for HRQoL outcomes after BC surgery.MethodsWe used three datasets of BC patients from Berlin, Germany; Ljubljana, Slovenia; and Rotterdam; Netherlands. We included non-metastasised patients who were surgically treated for an initial diagnosis of BC and completed pre- and postoperative validated questionnaires. We used linear mixed models to analyse 15 domains of the EORTC QLQ-C30 and EORTC QLQ-BR23 over a two-year horizon. Baseline domain score (measured pre-operatively), age, BMI, smoking, TN stage, receptor status, neoadjuvant chemotherapy, axillary surgery and surgery type (breast-conserving, mastectomy, and immediate implant-based reconstruction) were included as predictors. Predictive performance at validation was assessed by the proportion of variance explained (marginal R2; mR2).ResultsWe included N = 795 patients from Germany for development and N = 623 from Slovenia and N = 417 from Netherlands for validation. The largest proportion of variance was explained by the prediction models for sexual functioning (SF, mR2 35%), physical functioning (PF, mR2 29%), body image (BI, mR2 26%), and cognitive functioning (CF, mR2 25%). The models captured meaningfully different trends over time for different outcomes and surgery types. The predictive performance of the models was largely driven by the baseline domain score. Performance was reasonable at external validation, with r2 values of 19–33% for PF, 10–17% for CF, 15–18% for BI, and 22–28% for SF, although some other outcomes (e.g. breast symptoms and role functioning) showed miscalibration, indicating a need for recalibration.ConclusionHRQoL after breast cancer surgery can be predicted using simple models with baseline domain scores and surgery type, demonstrating a new opportunity for Patient-Reported Outcome Measures (PROMs) in personalized care.